search
Back to results

Statins for Acutely Injured Lungs From Sepsis (SAILS)

Primary Purpose

Sepsis, Acute Lung Injury

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Rosuvastatin
Placebo
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis focused on measuring ALI, Sepsis, statin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. Systemic inflammatory response syndrome (SIRS) defined as meeting at least criteria (a) or (b)for a systemic inflammatory response:

    1. White blood cell count >12,000 or <4,000 or >10% band forms
    2. Body temperature >38 degrees Celsius (C) (any route) or <36 degrees C (accepting core temperatures only; indwelling catheter, esophageal, rectal)
    3. Heart rate (> 90 beats/min) or receiving medications that slow heart rate or paced rhythm 2. Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and bacterial meningitis (Appendix A).

      3. ALI as defined by acute onset of:

    1. PaO2 / FiO2 ≤ 300 (intubated). If altitude > 1000m, then PaO2 / FiO2 ≤ 300 x (PB/760), and
    2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph, and
    3. Requirement for positive pressure ventilation via an endotracheal tube, and
    4. No clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg. If a patient has a PAOP > 18 mmHg, then the other criteria must persist for more than 12 hours after the PAOP has declined to ≤ 18 mmHg, and still be within the 48-hour enrollment window.

"Acute onset" is defined as follows: the duration of the hypoxemia criterion (#1) and the chest radiograph criterion (#2) must be ≤ 28 days at the time of randomization. Opacities considered "consistent with pulmonary edema" include any patchy or diffuse opacities not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (> 28 days). The findings of vascular redistribution, indistinct vessels, and indistinct cardiac borders are not considered "consistent with pulmonary edema".

All ALI criteria (3a-d above) must occur within the same 24 hour period. The onset of ALI is when the last ALI criterion is met. Patients must be enrolled within 48 hours of ALI onset and no more than 7 days from the initiation of mechanical ventilation. SIRS criteria must occur within the 72 hours before or the 24 hours after ALI onset. Information for determining when these time window criteria were met may come from either the Network hospital or a referring hospital reports.

Exclusion Criteria:

  1. No consent/inability to obtain consent
  2. Age less than 18 years
  3. More than 7 days since initiation of mechanical ventilation
  4. More than 48 hours since meeting ALI inclusion criteria
  5. Patient, surrogate, or physician not committed to full support ).
  6. Unable to receive or unlikely to absorb enteral study drug
  7. Rosuvastatin specific exclusions

    • Receiving a statin medication within 48 hours of randomization
    • Allergy or intolerance to statins
    • Physician insistence for the use or avoidance of statins during the current hospitalization
    • Creatine Kinase (CK) , alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal
    • Diagnosis of hypothyroidism and not on thyroid replacement therapy
    • Pregnancy or breast feeding
    • Receiving niacin, fenofibrate or cyclosporine, gemfibrozil, atazanavir, lopinavir, ritonavir, daptomycin
  8. Severe chronic liver disease
  9. Moribund patient not expected to survive 24 hours
  10. Chronic respiratory failure defined as PaCO2 > 60 mm Hg in the outpatient setting
  11. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for CPAP/BIPAP (Continuous Positive Airway Pressure/BiLevel Positive Airway Pressure) used solely for sleep-disordered breathing
  12. Diffuse alveolar hemorrhage from vasculitis
  13. Burns > 40% total body surface
  14. Interstitial lung disease of severity sufficient to require continuous home oxygen therapy
  15. Unwillingness or inability to utilize the ARDS network 6 ml/kg Predicted Body Weight (PBW) ventilation protocol
  16. Cardiac disease classified as NYHA (New York Heart Association) class IV
  17. Myocardial infarction within past 6 months
  18. Intraparenchymal Central Nervous System (CNS) bleed within a month of randomization.
  19. Temperature >40.3 C in the 6 hours before randomization

Sites / Locations

  • University of San Francisco-Fresno Medical Center
  • University of California, Davis Medical Center
  • UCSF-Moffitt Hospital
  • University of California, San Francisco (UCSF)-Moffitt Hospital
  • Centura St. Anthony Central Hospital
  • Denver Health Medical Center
  • Rose Medical Center
  • University of Colorado Health Sciences Center
  • Washington Hospital Center
  • Baton Rouge General Hospital-Blue Bonnet
  • Baton Rouge General Hospital-Midcity
  • Earl K. Long Medical Center
  • Our Lady of the Lake Regional Medical Center
  • Medical Center of Louisiana
  • Ochsner Clinic Foundation
  • Tulane University Health Sciences Center
  • Johns Hopkins Bayview Medical Center
  • Johns Hopkins Hospital
  • University of Maryland Shock Trauma Center
  • Baystate Medical Center
  • Rochester Methodist Hospital
  • St. Mary's Hospital, Mayo Clinic
  • Duke University Medical Center
  • Durham Regional Medical Center
  • Moses Cone Health System
  • Wesley Long Community Hospital
  • Wake Forest University Baptist Medical Center
  • Cleveland Clinic Foundation
  • MetroHealth Medical Center
  • University Hospitals of Cleveland
  • Vanderbilt University Medical Center
  • Baylor College of Medicine
  • Intermountain Medical Center
  • McKay-Dee Hospital
  • Utah Valley Regional Medical Center
  • LDS Hospital
  • University of Virginia Medical Center
  • Providence Hospital
  • Harborview Medical Center
  • University of Washington

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Rosuvastatin

Placebo

Arm Description

Half of the subjects were randomized to the active drug (Rosuvastatin). Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy. Duration: drug was administered daily until: 28 days after randomization or 3 days after ICU discharge (whichever comes first), Discharge from study hospital, Death

Half of the subjects were randomized to placebo. 10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug.

Outcomes

Primary Outcome Measures

Hospital Mortality to Day 60.
The percentage of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.

Secondary Outcome Measures

Ventilator Free Days at Study Day 28
Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.

Full Information

First Posted
September 16, 2009
Last Updated
April 12, 2016
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00979121
Brief Title
Statins for Acutely Injured Lungs From Sepsis
Acronym
SAILS
Official Title
Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Terminated
Why Stopped
stopped for futility
Study Start Date
January 2010 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
Detailed Description
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) involves extensive inflammation in the lungs that can lead to rapid respiratory failure. These conditions are most commonly caused by pneumonia, generalized infection, or severe trauma to the lungs, but can also be less commonly caused by smoke or salt water inhalation, drug overdose, or shock. For some people, ALI/ARDS resolves without treatment, but many severe cases result in hospitalization in the intensive care unit (ICU), where 30% to 40% of cases end in mortality. Current treatments for ALI/ARDS include assisted breathing with a ventilator, supportive care, and management of the underlying causes. Upon admission to the ICU, Rosuvastatin or placebo was administered through an enteral feeding tube or administered orally following extubation when patients were able to safely take oral medications. The type and placement of the enteral feeding tube (nasogastric, nasoenteric, PEG, orogastric, oroenteric, etc.) and the ability to safely take oral medications was determined by the patient's primary team. Study drug was blinded with an identical appearing placebo. The first study drug dose (rosuvastatin or placebo) was administered within 4 hours of randomization as a loading dose of 40 mg. Blood pressure, heart rate, ventilation settings, and various blood factors were measured during treatment. Phone-based follow-up assessments occurred at months 6 and 12 after ICU discharge and included measurements of health-related quality of life; psychological, neurocognitive, and physical activity outcomes; healthcare utilization; and mortality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Acute Lung Injury
Keywords
ALI, Sepsis, statin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
745 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rosuvastatin
Arm Type
Active Comparator
Arm Description
Half of the subjects were randomized to the active drug (Rosuvastatin). Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy. Duration: drug was administered daily until: 28 days after randomization or 3 days after ICU discharge (whichever comes first), Discharge from study hospital, Death
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Half of the subjects were randomized to placebo. 10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug.
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin
Other Intervention Name(s)
Crestor
Intervention Description
Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
Primary Outcome Measure Information:
Title
Hospital Mortality to Day 60.
Description
The percentage of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.
Time Frame
60 days after randomization
Secondary Outcome Measure Information:
Title
Ventilator Free Days at Study Day 28
Description
Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.
Time Frame
time of initiating unassisted breathing to day 28 after study randomization
Other Pre-specified Outcome Measures:
Title
Organ Failure Free Days at Day 14
Description
The number of days from randomization to day 14 without an organ failure. Four main organ systems were measured: cardiovascular, coagulation, hepatic function, and renal function.
Time Frame
14 days after randomization
Title
ICU Free Days to Day 28
Time Frame
28 days after randomization
Title
Other Secondary Out-comes
Description
Percentage of subjects with Arrhythmia's, Bowel Ischemia, Myocardial Infarction, Ischemic Stroke, and Thromboembolism were measured.
Time Frame
28 days after randomization
Title
Changes in Plasma Concentrations of C-reactive Protein (CRP) From Baseline to Day 6 and Day 14
Description
CRP levels were collected on subjects at baseline and on-study. The change in concentration from baseline levels to levels on study days 6 and 14 was analyzed. Those subjects that were still alive and on study at day 6 and 14 with a measured CRP level were included in the analysis.
Time Frame
6 and 14 days after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Systemic inflammatory response syndrome (SIRS) defined as meeting at least criteria (a) or (b)for a systemic inflammatory response: White blood cell count >12,000 or <4,000 or >10% band forms Body temperature >38 degrees Celsius (C) (any route) or <36 degrees C (accepting core temperatures only; indwelling catheter, esophageal, rectal) Heart rate (> 90 beats/min) or receiving medications that slow heart rate or paced rhythm 2. Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and bacterial meningitis (Appendix A). 3. ALI as defined by acute onset of: PaO2 / FiO2 ≤ 300 (intubated). If altitude > 1000m, then PaO2 / FiO2 ≤ 300 x (PB/760), and Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph, and Requirement for positive pressure ventilation via an endotracheal tube, and No clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg. If a patient has a PAOP > 18 mmHg, then the other criteria must persist for more than 12 hours after the PAOP has declined to ≤ 18 mmHg, and still be within the 48-hour enrollment window. "Acute onset" is defined as follows: the duration of the hypoxemia criterion (#1) and the chest radiograph criterion (#2) must be ≤ 28 days at the time of randomization. Opacities considered "consistent with pulmonary edema" include any patchy or diffuse opacities not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (> 28 days). The findings of vascular redistribution, indistinct vessels, and indistinct cardiac borders are not considered "consistent with pulmonary edema". All ALI criteria (3a-d above) must occur within the same 24 hour period. The onset of ALI is when the last ALI criterion is met. Patients must be enrolled within 48 hours of ALI onset and no more than 7 days from the initiation of mechanical ventilation. SIRS criteria must occur within the 72 hours before or the 24 hours after ALI onset. Information for determining when these time window criteria were met may come from either the Network hospital or a referring hospital reports. Exclusion Criteria: No consent/inability to obtain consent Age less than 18 years More than 7 days since initiation of mechanical ventilation More than 48 hours since meeting ALI inclusion criteria Patient, surrogate, or physician not committed to full support ). Unable to receive or unlikely to absorb enteral study drug Rosuvastatin specific exclusions Receiving a statin medication within 48 hours of randomization Allergy or intolerance to statins Physician insistence for the use or avoidance of statins during the current hospitalization Creatine Kinase (CK) , alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal Diagnosis of hypothyroidism and not on thyroid replacement therapy Pregnancy or breast feeding Receiving niacin, fenofibrate or cyclosporine, gemfibrozil, atazanavir, lopinavir, ritonavir, daptomycin Severe chronic liver disease Moribund patient not expected to survive 24 hours Chronic respiratory failure defined as PaCO2 > 60 mm Hg in the outpatient setting Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for CPAP/BIPAP (Continuous Positive Airway Pressure/BiLevel Positive Airway Pressure) used solely for sleep-disordered breathing Diffuse alveolar hemorrhage from vasculitis Burns > 40% total body surface Interstitial lung disease of severity sufficient to require continuous home oxygen therapy Unwillingness or inability to utilize the ARDS network 6 ml/kg Predicted Body Weight (PBW) ventilation protocol Cardiac disease classified as NYHA (New York Heart Association) class IV Myocardial infarction within past 6 months Intraparenchymal Central Nervous System (CNS) bleed within a month of randomization. Temperature >40.3 C in the 6 hours before randomization
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathon Truwit, MD
Organizational Affiliation
University of Virginia, Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
University of San Francisco-Fresno Medical Center
City
Fresno
State/Province
California
Country
United States
Facility Name
University of California, Davis Medical Center
City
Sacramento
State/Province
California
Country
United States
Facility Name
UCSF-Moffitt Hospital
City
San Francisco
State/Province
California
Country
United States
Facility Name
University of California, San Francisco (UCSF)-Moffitt Hospital
City
San Francisco
State/Province
California
Country
United States
Facility Name
Centura St. Anthony Central Hospital
City
Denver
State/Province
Colorado
Country
United States
Facility Name
Denver Health Medical Center
City
Denver
State/Province
Colorado
Country
United States
Facility Name
Rose Medical Center
City
Denver
State/Province
Colorado
Country
United States
Facility Name
University of Colorado Health Sciences Center
City
Denver
State/Province
Colorado
Country
United States
Facility Name
Washington Hospital Center
City
Washington DC
State/Province
District of Columbia
Country
United States
Facility Name
Baton Rouge General Hospital-Blue Bonnet
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
Baton Rouge General Hospital-Midcity
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
Earl K. Long Medical Center
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
Our Lady of the Lake Regional Medical Center
City
Baton Rouge
State/Province
Louisiana
Country
United States
Facility Name
Medical Center of Louisiana
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
Ochsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
Tulane University Health Sciences Center
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
Johns Hopkins Bayview Medical Center
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Johns Hopkins Hospital
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
University of Maryland Shock Trauma Center
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Baystate Medical Center
City
Springfield
State/Province
Massachusetts
Country
United States
Facility Name
Rochester Methodist Hospital
City
Rochester
State/Province
Minnesota
Country
United States
Facility Name
St. Mary's Hospital, Mayo Clinic
City
Rochester
State/Province
Minnesota
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
Country
United States
Facility Name
Durham Regional Medical Center
City
Durham
State/Province
North Carolina
Country
United States
Facility Name
Moses Cone Health System
City
Greensboro
State/Province
North Carolina
Country
United States
Facility Name
Wesley Long Community Hospital
City
Greensboro
State/Province
North Carolina
Country
United States
Facility Name
Wake Forest University Baptist Medical Center
City
Winston Salem
State/Province
North Carolina
Country
United States
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
MetroHealth Medical Center
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
University Hospitals of Cleveland
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
Country
United States
Facility Name
Intermountain Medical Center
City
Murray
State/Province
Utah
Country
United States
Facility Name
McKay-Dee Hospital
City
Ogden
State/Province
Utah
Country
United States
Facility Name
Utah Valley Regional Medical Center
City
Provo
State/Province
Utah
Country
United States
Facility Name
LDS Hospital
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
University of Virginia Medical Center
City
Charlottesville
State/Province
Virginia
Country
United States
Facility Name
Providence Hospital
City
Everett
State/Province
Washington
ZIP/Postal Code
98201
Country
United States
Facility Name
Harborview Medical Center
City
Seattle
State/Province
Washington
Country
United States
Facility Name
University of Washington
City
Seattle
State/Province
Washington
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
36119770
Citation
Yu SY, Ge ZZ, Xiang J, Gao YX, Lu X, Walline JH, Qin MB, Zhu HD, Li Y. Is rosuvastatin protective against sepsis-associated encephalopathy? A secondary analysis of the SAILS trial. World J Emerg Med. 2022;13(5):367-372. doi: 10.5847/wjem.j.1920-8642.2022.072.
Results Reference
derived
PubMed Identifier
26936876
Citation
Dinglas VD, Hopkins RO, Wozniak AW, Hough CL, Morris PE, Jackson JC, Mendez-Tellez PA, Bienvenu OJ, Ely EW, Colantuoni E, Needham DM. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax. 2016 May;71(5):401-10. doi: 10.1136/thoraxjnl-2015-208017. Epub 2016 Mar 2.
Results Reference
derived
PubMed Identifier
26832963
Citation
Needham DM, Colantuoni E, Dinglas VD, Hough CL, Wozniak AW, Jackson JC, Morris PE, Mendez-Tellez PA, Ely EW, Hopkins RO. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial. Lancet Respir Med. 2016 Mar;4(3):203-12. doi: 10.1016/S2213-2600(16)00005-9. Epub 2016 Jan 29.
Results Reference
derived
PubMed Identifier
24835849
Citation
National Heart, Lung, and Blood Institute ARDS Clinical Trials Network; Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014 Jun 5;370(23):2191-200. doi: 10.1056/NEJMoa1401520. Epub 2014 May 18.
Results Reference
derived
Links:
URL
http://www.ardsnet.org
Description
ARDS Network Website
Available IPD and Supporting Information:
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
http://biolincc.nhlbi.nih.gov/studies/sails/
Available IPD/Information Identifier
ARDSNet-SAILS
Available IPD/Information Comments
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
http://biolincc.nhlbi.nih.gov/studies/sails/
Available IPD/Information Type
Study Forms
Available IPD/Information URL
http://biolincc.nhlbi.nih.gov/studies/sails/

Learn more about this trial

Statins for Acutely Injured Lungs From Sepsis

We'll reach out to this number within 24 hrs